RT Journal Article
SR Electronic
T1 Role of Drugs Affecting the Renin-Angiotensin-Aldosterone System on Susceptibility and Severity of COVID-19: A Large Case-Control Study from Zheijang Province, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.24.20077875
DO 10.1101/2020.04.24.20077875
A1 Yan, Huadong
A1 Valdes, Ana M
A1 Vijay, Amrita
A1 Wang, Shanbo
A1 Liang, Lili
A1 Yang, Shiqing
A1 Wang, Hongxia
A1 Tan, Xiaoyan
A1 Du, Jingyuan
A1 Jin, Susu
A1 Huang, Kecheng
A1 Jiang, Fanrong
A1 Zhang, Shun
A1 Zheng, Nanhong
A1 Hu, Yaoren
A1 Cai, Ting
A1 Aithal, Guruprasad P.
YR 2020
UL http://medrxiv.org/content/early/2020/04/29/2020.04.24.20077875.abstract
AB Background Medical editorials have suggested that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) should not be given to people with arterial hypertension during the coronavirus disease 2019 (COVID-19) pandemic because of a potential increased risk of worse clinical outcomes and that calcium channel blockers (CCBs) should be used as an alternative.Methods Using a cohort of 610 COVID-19 cases and 48,667 population-based controls from Zheijang, China we have tested the role of usage of ACEIs, ARBs, CCBs and other medications on risk and severity of COVID 19. Analyses were adjusted for age, sex and BMI and for presence of relevant comorbidities.Findings Higher BMI, diabetes and cardio/ cerebrovascular disease are independent risk factors for the development of COVID-19. Individuals with hypertension taking CCBs had significantly increased risk [odds ratio (OR)= 1.67 (95% CI 1.2-2.9)) of manifesting symptoms of COVID-19 whereas those taking ARBs and diuretics had significantly lower disease risk (OR=0.24; 95%CI 0.17-0.34 and OR=0.32; 95%CI 0.19-0.57 respectively). Other antihypertensive drugs were not associated with increased risk of severe or critical form of the infection. Use of glucocorticoids was significantly associated with a severe/critical form of COVID-19 (OR= 7.56; 95%CI 1.17-48.93).Interpretation We found no evidence to alter ARBs or ACEIs therapy in the context of the pandemic. Patients on corticosteroids with COVID-19 are at higher risk of developing a severe form of COVID-19and therefore should be monitored closely.Funding By the Social Development Major Projects of Ningbo City (2016C51005), Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2018ZD039), Zhejiang Provincial natural science foundation (LGF20H030006) and by the NIHR Nottingham Biomedical Research Centre (Reference no: BRC-1215-20003).Competing Interest StatementGPA is an advisory board member for Amryt Pharmaceuticals, Astra Zeneca, GSK, and Pfizer. AMV is a consultant for Zoe Global Ltd and member of the scientific advisory board of CPKelco. Funding StatementFunded by the Social Development Major Projects of Ningbo City (2016C51005), Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (2018ZD039), Zhejiang Provincial natural science foundation (LGF20H030006) and by the NIHR Nottingham Biomedical Research Centre (Reference no: BRC-1215-20003).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the current analysis will be made available on request. The data has currently not been uploaded on a repository or online database.